ProShares UltraShort NASDAQ Biotechnology
9 hedge funds and large institutions have $1.88M invested in ProShares UltraShort NASDAQ Biotechnology in 2017 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
25% less funds holding
Funds holding: 12 → 9 (-3)
29% less capital invested
Capital invested by funds: $2.62M → $1.88M (-$749K)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Holders
9
Holding in Top 10
1
Calls
$689K
Puts
$241K
Top Buyers
| 1 | +$236K | |
| 2 | +$78.4K | |
| 3 | +$12.9K | |
| 4 |
AG
Advisor Group
Phoenix,
Arizona
|
+$10K |
Top Sellers
| 1 | -$283K | |
| 2 | -$260K | |
| 3 | -$100K | |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$68.4K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$36.9K |